The voluntary price cut made by the overactive bladder treatment Vesicare (solifenacin succinate) is expected to reduce its drug price to a level lower than its generic versions.

On what tactic the generic companies will take after losing their price competitivity remains the focus of attention.

According to industry sources on the 20th, Astellas Korea has voluntarily applied to lower the reimbursement ceiling for Vesicare from ₩533 to ₩516, which will become effective as of March 1st. The price will be applied to both the 5mg and 10mg doses.

The price ceiling of the discounted Vesicare 5mg will be set at the third-lowest level among the 78 products with the s